Core Viewpoint - The company Aihuilong is under investigation by the China Securities Regulatory Commission (CSRC) for allegedly misleading statements, marking a significant shift in regulatory scrutiny within the capital market [1][5][16]. Group 1: Company Background - Aihuilong, a star listed company on the Sci-Tech Innovation Board, was founded by Hu De Ming in 2008 and has been led by his son, Hu Kunhui, since 2012 [9][10]. - The company gained prominence during the COVID-19 pandemic, achieving a revenue of 39.81 billion yuan and a net profit of 10.22 billion yuan in 2022, but has since faced a significant decline in performance [12][13]. Group 2: Recent Events - Aihuilong held a celebratory annual meeting on February 3, 2026, shortly before the CSRC announced the investigation on February 6, highlighting a stark contrast between the company's optimistic public image and its regulatory challenges [2][5][4]. - Following the announcement of the investigation, Aihuilong's stock price plummeted to a historical low of 13.53 yuan, representing a 69.9% decrease in market value since its IPO [5][12]. Group 3: Regulatory Environment - The CSRC's investigation into Aihuilong is part of a broader trend of intensified regulatory scrutiny in the Chinese capital market, with an average of one company being investigated every five days since the beginning of 2026 [1][16]. - The regulatory response to Aihuilong's misleading announcement regarding a partnership in brain-computer interface technology reflects a zero-tolerance approach to information disclosure violations [6][17]. Group 4: Financial Performance - Aihuilong's financial performance has deteriorated sharply, with a projected net profit drop of 90.05% to 93.37% for 2025, attributed to a decline in COVID-related business and market demand [12][13]. - The company's international business has shown some growth, with overseas revenue reaching 2.08 billion yuan in the first three quarters of 2025, a 39.39% increase year-on-year [12].

Core Viewpoint - The company Aihuilong is under investigation by the China Securities Regulatory Commission (CSRC) for allegedly misleading statements, marking a significant shift in regulatory scrutiny within the Chinese capital market [1][5][16]. Group 1: Company Background - Aihuilong, a star listed company on the Sci-Tech Innovation Board, was founded by Hu De Ming, who transitioned from a public servant to a businessman, establishing the company in 2008 [9]. - Hu Kunhui, the 35-year-old chairman and CEO, took control of the company at the age of 21 due to family circumstances and has since positioned himself as a prominent figure in the industry [9][10]. - The company experienced explosive growth during the COVID-19 pandemic, with revenue soaring to 39.81 billion yuan in 2022, but has since faced a significant decline in performance [12]. Group 2: Recent Events - Aihuilong held a celebratory annual meeting on February 3, 2026, just days before the CSRC announced the investigation, highlighting a stark contrast between the company's optimistic public image and its underlying issues [2][4][5]. - Following the announcement of the investigation on February 6, the company's stock price plummeted to a historical low of 13.53 yuan, representing a 69.9% decrease in market value since its IPO [5][12]. Group 3: Regulatory Environment - The investigation into Aihuilong is part of a broader trend of intensified regulatory scrutiny in the Chinese capital market, with an average of one company being investigated every five days since the beginning of 2026 [1][16][17]. - The CSRC's actions reflect a "zero tolerance" approach to misleading disclosures, aiming to reshape the market's regulatory landscape [1][17]. Group 4: Financial Performance - Aihuilong's financial performance has deteriorated sharply, with a projected net profit drop of 90.05% to 93.37% for 2025, attributed to a decline in demand and adverse market conditions [12][13]. - The company's international business has shown some resilience, with overseas revenue increasing by 39.39% in the first three quarters of 2025, indicating potential for future growth despite domestic challenges [12]. Group 5: Shareholder Actions - Amid declining stock prices, significant shareholders, including Hu Kunhui, initiated a plan to reduce their holdings, raising concerns about the company's future prospects [14][15]. - The timing of these share reductions during a market rally has led to speculation regarding the motivations behind these actions, suggesting a cautious outlook on the company's short-term future [15].

2月6日，证监会官网发布公告称，对亚辉龙公告涉嫌误导性陈述立案调查。 据悉，2026年1月7日，深圳市亚辉龙生物科技股份有限公司(简称亚辉龙)披露签署战略合作框架协议的公告，涉嫌误导性陈述。近日，证监会已对亚辉龙 立案调查。下一步，将在全面调查的基础上依法处理，切实维护市场健康发展。 *有什么想说的，欢迎给我们留言哦* 同日，亚辉龙亦发布关于收到中国证券监督管理委员会立案告知书的公告。 亚辉龙表示，公司于2026年2月6日收到中国证券监督管理委员会(以下简称"中国证监会")下发的《立案告知书》，因涉嫌信息披露违法违规，根据《中华 人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司予以立案。 亚辉龙此次被查与此前披露的公告相关。1月6日晚，亚辉龙发布公告称，于近日与深圳脑机星链科技有限公司(以下简称："脑机星链")签署了《战略合作 框架协议》。双方将通过整合脑机接口技术与临床和市场资源，共同开发脑机接口相关在研产品及推进后续市场拓展及推广。亚辉龙同时强调，本次签署 的协议为意向性约定，不涉及具体金额，无需提交公司董事会、股东大会审议。 同日，上交所就紧急向亚辉龙发送了问询函，并对亚辉 ...

2月26日，证监会官网发布公告称，对亚辉龙公告涉嫌误导性陈述立案调查。 据悉，2026年1月7日，深圳市亚辉龙生物科技股份有限公司（简称亚辉龙）披露签署战略合作框架协议 的公告，涉嫌误导性陈述。近日，证监会已对亚辉龙立案调查。下一步，将在全面调查的基础上依法处 理，切实维护市场健康发展。 同日，亚辉龙亦发布关于收到中国证券监督管理委员会立案告知书的公告。 亚辉龙表示，公司于2026年2月6日收到中国证券监督管理委员会（以下简称"中国证监会"）下发的《立 案告知书》，因涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚 法》等法律法规，中国证监会决定对公司予以立案。 亚辉龙此次被查与此前披露的公告相关。1月6日晚，亚辉龙发布公告称，于近日与深圳脑机星链科技有 限公司（以下简称："脑机星链"）签署了《战略合作框架协议》。双方将通过整合脑机接口技术与临床 和市场资源，共同开发脑机接口相关在研产品及推进后续市场拓展及推广。亚辉龙同时强调，本次签署 的协议为意向性约定，不涉及具体金额，无需提交公司董事会、股东大会审议。 同日，上交所就紧急向亚辉龙发送了问询函，并对亚辉龙及有关责任人予以监管警示的 ...

据中国证监会2月6日消息，近日，证监会对深圳市亚辉龙生物科技股份有限公司(以下简称"亚辉龙")立案调查。据悉，1月7日，亚辉龙披露签署战略合作 框架协议的公告，涉嫌误导性陈述。证监会表示，下一步，将在全面调查的基础上依法处理，切实维护市场健康发展。 此前，在"脑机接口"热潮之下，亚辉龙因信披"蹭热点"被上海证券交易所(以下简称"上交所")监管警示。 同日，亚辉龙披露公告称，于2月6日收到中国证监会的《立案告知书》，因涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行 政处罚法》等法律法规，中国证监会决定对公司予以立案。目前公司各项经营活动和业务均正常开展。立案调查期间，公司将积极配合中国证监会的相关 工作，并严格按照相关法律法规和监管要求及时履行信息披露义务。 从二级市场表现看，1月6日，亚辉龙股价上涨6.52%、成交量较前一个交易日增长299%。 1月6日晚间，亚辉龙发布《关于自愿披露签署战略合作框架协议的公告》。根据公告，亚辉龙宣布与深圳脑机星链科技有限公司(以下简称"脑机星链")签 署战略合作框架协议，双方共同达成战略合作，通过整合脑机接口技术与临床和市场资源，共同开发脑机接口相关在研 ...

Core Viewpoint - The company, Aihuilong (688575), has signed a strategic cooperation framework agreement with Shenzhen Brain-Machine Starlink Technology Co., Ltd. to integrate brain-machine interface technology with clinical and market resources for the development of related products and market expansion in the field of central nervous system diseases [1]. Group 1 - The strategic cooperation aims to enhance diagnostic and treatment technology levels for central nervous system diseases [1]. - The agreement is valid for five years and is not expected to have a significant impact on Aihuilong's performance for the current year [1]. - Future performance impact will depend on the progress of specific projects under this cooperation [1].